Moderna received Health Canada authorization for second Omicron-targeting bivalent booster
On Nov. 4, 2022, Moderna announced that Health Canada had authorized the use of its BA.4/BA.5 Omicron-targeting bivalent…
Pfizer and BioNTech announced updated data for Omicron BA.4/BA.5-adapted bivalent booster
On Nov. 4, 2022, Pfizer and BioNTech announced updated data from a Phase 2/3 clinical trial demonstrating a…
Hologic announced contract with BARDA to support IVD approval of COVID assays
On Nov. 2, 2022, Hologic announced that it had been awarded a $19 million contract from the Biomedical…
Biotechnology | COVID-19 | Diagnostics | Disease | NIH | Therapeutics
NIH-funded study showed blood pressure levels rose during pandemic
On Nov. 1, 2022, the National Institutes of Health (NIH) announced that adults with hypertension saw a small,…
Japan approved partial change to a NDA for Omicron-targeting bivalent booster COVID-19 vaccine
On Oct. 31, 2022, Moderna announced that it had received approval from the Ministry of Health, Labour and…
INOVIO Discontinued internal efforts to develop INO-4800 as COVID-19 heterologous booster vaccine Candidate
On Oct. 27, 2022, Inovio Pharma announced that it has discontinued its internally funded efforts to develop INO-4800…
University of Washington reported global COVID cases will increase in coming months, but at a slower pace
On Oct. 25, 2022, the University of Washington reported that daily global COVID-19 infections were projected to rise…
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Nanotechnology | Therapeutics | Vaccine
COVID-causing virus in air detected with high-tech bubbles
On Oct. 25, 2022, Pacific Northwest National Laboratory (PNNL) announced that scientists have shown that they can detect…
U.S. FDA recommended Novavax COVID-19 vaccine, adjuvanted as a booster in adults
On Oct. 19, 2022, the U.S. Food and Drug Administration (FDA) recommended the use of the Novavax COVID-19…
EMA’s CHMP for Human Use issued positive opinion recommending authorization for use of Spikevax in children 6 months – 5 years in EU
On Oct. 19, 2022, Moderna announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…
90-Day analysis showed Moderna’s Omicron BA.1-targeting bivalent vaccine, mRNA-1273.214, demonstrated superior antibody response
On Oct. 19, 2022, Moderna announced new clinical data on its bivalent Omicron-containing booster, mRNA-1273.214. Ninety days after…
Pfizer and BioNTech received positive CHMP ppinion for COMIRNATYﾮ in children 6 months to less than 5 lears in EU
On Oct. 19, 2022, Pfizer and BioNTech announced that the European Medicines Agencyﾒs (EMA) Committee for Medicinal Products…
Moderna announced supply agreement with Gavi that secured access to updated variant-specific COVID-19 vaccines for low-and-middle income countries
On Oct. 17, 2022, Moderna and Gavi, the Vaccine Alliance, announced they had mutually agreed to cancel remaining…
Novavax COVID-19-influenza combination vaccine candidate induced antibody and T-Cell responses against SARS-CoV-2 and influenza
On Oct. 13, 2022, Novavax announced positive results from the Phase 1/2 clinical trial of its COVID-19-Influenza Combination…
Pfizer and BioNTech announced positive early data from clinical trial of Omicron BA.4/BA.5-adapted bivalent booster
On Oct. 13, 2022, Pfizer and BioNTech announced early data from a Phase 2/3 clinical trial (NCT05472038) evaluating…
Gene associated with better immune response and protection after COVID-19 vaccination identified by Oxford researchers
On Oct. 13, 2022, researchers from the University of Oxford reported findings from a study exploring how certain…
Moderna received Authorization for Emergency Use from FDA of Omicron-targeting bivalent COVID-19 booster vaccine for children
On Oct. 12, 2022, Moderna announced that it had received emergency use authorization from the U.S. Food and…
Biotechnology | CDC | COVID-19 | FDA
Pfizer and BioNTech received U.S. FDA EUA for Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster in children
On Oct. 12, 2022, Pfizer and BioNTech announced that the U.S. Food and Drug Administration granted Emergency Use…
Intranasal COVID-19 vaccine candidateﾒs clinical data highlighted need for further development of nasal spray vaccines
On Oct. 11, 2022, researchers from the University of Oxford have reported new findings from a Phase 1…
Novavax and SK bioscience filed post approval change application in South Korea for Nuvaxovid COVID-19 vaccine as booster in adults
On Oct. 10, 2022, Novavax announced that partner, SK bioscience, had submitted a Post Approval Change Application to…
Switzerland’s Federal Office of Public Health recommended Novavax Nuvaxovid COVID-19 vaccine as booster in adults
On Oct. 10, 2022, Novavax announced that Switzerland’s Federal Office of Public Health had recommended Nuvaxovid (NVX-CoV2373) as…
Pfizer and BioNTech’s Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster received Health Canada authorization for individuals 12 years of age and older
On Oct. 7, 2022, Pfizer and BioNTech announced that Health Canada had authorized COMIRNATY Original & Omicron BA.4/BA.5…
Japanese vaccine database Created to assess Vaccine Effectiveness and adverse events
On Oct. 6, 2022, researchers in Japan released a study that described the development and application of the…
Merck and Ridgeback Biotherapeutics provided update on new clinical and non-clinical studies of LAGEVRIOﾙ (molnupiravir)
On Oct. 6, 2022, Merck announced data from two real-world evidence studies evaluating LAGEVRIOﾙ (molnupiravir), an investigational oral…
Washington University in St. Louis COVID-19 nasal vaccine technology licensed to Ocugen
On Oct. 4, 2022, Washington University in St. Louis announced it had licensed the rights to develop, manufacture…
Pfizer and BioNTech completed submission to EMA for Omicron BA.4/BA.5-adapted bivalent vaccinebBooster in children 5 through 11 years of age
On Sept. 28, 2022, Pfizer and BioNTech announced they had completed a submission to the European Medicines Agency…
EMA accepted Moderna’s conditional Marketing Authorization filing for omicron BA.4/BA.5 targeting bivalent COVID-19 vaccine
On Sept. 28, 2022, Moderna announced that the European Medicines Agency (EMA) had accepted a variation for the…
Study confirmed link between COVID-19 vaccination and temporary increase in menstrual cycle length
On Sept. 27, 2022, the National Institutes of Health (NIH) announced that a large international study had confirmed…
Novavax made one million doses of Nuvaxovid available for use in the United Kingdom
On Sept. 27, 2022, Novavax announced that an initial one million doses of Nuvaxovid (NVX-CoV2373) COVID-19 vaccine were…
Biotechnology | COVID-19 | FDA
Pfizer and BioNTech submitted application to U.S. FDA for EUA of Omicron BA.4/BA.5-adapted bivalent vaccine booster in children 5 through 11 years of age
On Sept. 28, 2022, Pfizer and BioNTech announced they have completed a submission to the U.S. Food and…